New-Onset T1D Trials
Many immunotherapy clinical trials target individuals who have recently been diagnosed with type 1 diabetes, with goals to preserve their beta cell function and prevent disease progression. Find the list of clinical trials offered in the area along with contact information and links to more information.
GLADIATOR
A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with recent onset type 1 diabetes and a low residual B-cell function at baseline.
Joslin Diabetes Center, Boston, MA
Clinical Trials Website
Not Recruiting
ITN DESIGNATE
A T cell phenotype signature driven dose finding study with siplizumab in type 1 diabetes mellitus
Joslin Diabetes Center, Boston, MA
DESIGNATE Study Website
Not Recruiting
T1D RELAY
Rituximab-pvvr / Abatacept Newly Diagnosed Study
Naomi Berrie Diabetes Center, New York, NY
Yale University, New Haven, CT
T1D RELAY Trial Website
JAKPOT T1D
JAK Inhibitors Newly Diagnosed Study
Naomi Berrie Diabetes Center, New York, NY
Yale University, New Haven, CT
JAKPOT T1D Trial Website
- The safety and scientific validity of a research study is the responsibility of the study investigators and the study sponsor.
- It is important to evaluate the risks and potential benefits of clinical studies and to talk to your health care provider(s) before participating in a study.